Broadcom named strategic vendor for Walmart virtualization solutions
CAMBRIDGE, MA—James R. Kasinger, General Counsel and Secretary of CRISPR Therapeutics AG (NASDAQ:CRSP), a $3.7 billion market cap biotechnology company, recently reported a series of stock transactions involving the company’s common shares. According to the SEC filing, Kasinger sold a total of 3,966 shares over two days, generating proceeds of $169,242. The shares were sold at prices ranging from $42.42 to $43.32, near the current trading price of $43.49. InvestingPro analysis indicates the stock has shown significant volatility, trading between $36.52 and $76.86 over the past 52 weeks.
The transactions, filed on March 12, 2025, detail that on March 11, Kasinger sold 2,850 shares at $42.42 each, and on March 12, he sold an additional 1,116 shares at $43.32 each. These sales were executed to cover tax withholding obligations related to the vesting of restricted stock units, as mandated by the company’s RSU Settlement Policy. According to InvestingPro data, CRISPR Therapeutics maintains strong liquidity with a current ratio of 22.07, and holds more cash than debt on its balance sheet.
Following these transactions, Kasinger holds 78,664 shares of CRISPR Therapeutics. With six analysts recently revising earnings estimates upward for the upcoming period, investors can access comprehensive analysis and additional insights through the detailed Pro Research Report available on InvestingPro.
In other recent news, CRISPR Therapeutics has seen varied assessments from several analyst firms. Evercore ISI upgraded CRISPR Therapeutics from an In Line to an Outperform rating, raising the price target significantly from $60 to $99. This upgrade is based on anticipated pivotal developments, including the potential of in vivo programs CTX320 and CTX310. Citi, while maintaining a Buy rating, lowered its price target to $82, citing an underappreciation of Casgevy and the company’s developmental pipeline. Stifel also adjusted its outlook, reducing the price target to $49 and maintaining a Hold rating, expressing caution about the market uptake of Casgevy.
Meanwhile, TD Cowen upgraded CRISPR Therapeutics from Sell to Hold, keeping the price target steady at $35, acknowledging reduced downside risk. The company’s pipeline is under scrutiny, with expectations for data updates on CTX112 and other programs in 2025. CRISPR Therapeutics reported growth in Casgevy cell collections, with over 50 new collections in the final nine weeks of the fourth quarter. As these developments unfold, the company’s strategic direction and pipeline advancements remain focal points for investors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.